Latest news with #MemorialSloanKettering
Yahoo
19-07-2025
- Health
- Yahoo
Woman thought she had a pulled muscle working out. It was a rare cancer.
Jennifer Frederick was in the best shape of her life in 2023, so when she felt a small lump in her groin area after a week of workouts. She thought it was just a pulled muscle, but a month later, the lump was still there. Four months later, the lump was growing. Frederick went to a dermatologist and testing found more lumps in her leg. She scheduled a biopsy. On December 14, surgeons cut into her leg and removed the largest lumps. A week later, she had a diagnosis: Metastatic malignant melanoma. The disease is usually heralded by a mole on the skin, but Frederick never had one. More tests showed the cancer wasn't just in her leg. One scan found four lesions on her lungs. Another found five lesions on her brain. The results were shocking, Frederick said. "I never had a migraine, headache, blurry vision, never had problems breathing, never had a cough," Frederick, 50, said. "I never felt off at all." What is metastatic malignant melanoma? Melanoma is the deadliest form of skin cancer. Metastatic melanoma is any time of cancerous melanoma that has spread from one location to another, said Dr. Michael Postow, a medical oncologist at Memorial Sloan Kettering, who was not involved in Frederick's treatment. Metastatic malignant melanoma refers to late-stage metastatic melanoma. "Melanoma is a kind of cancer that can spread pretty widely throughout the body," Postow said. "It's one of the cancers that frequently involves the brain, so spread from melanoma to the brain ... can be quite a common occurrence. The lung is also a common site of metastatic melanoma." Typically, melanoma is recognized by a brown or black mole on the skin. Postow said it's unusual but not unheard of for a patient to have no mole or a "microscopic" one. He said that in addition to keeping an eye out for a new mole or an existing mole that changes color, size or texture, people should watch for lumps under the skin like the one Frederick had. Any concerns should be brought to a dermatologist, Postow said. The five-year survival rate for patients with advanced metastatic melanoma is about 35%, according to the American Cancer Society. Postow said clinical trials show that for patients who receive certain immunotherapy treatments, that number rises to 50%. Just a decade ago, the five-year survival rate was closer to 10%, he said. Immunotherapy was what Frederick's doctor, Cleveland Clinic medical oncologist Dr. Lucy Boyce Kennedy, recommended. The two talked over the options and decided to go with an intensive treatment that would combine gamma knife radiation and two immunotherapy drugs. Kennedy described the treatment protocol as "fairly high risk" and warned it could lead to the immune system attacking other organs. Frederick was undeterred. "She explained what this was going to look like. And I looked at her and I said, 'I don't care what it is. If it's the most aggressive treatment, I'm willing to do whatever it is,'" Frederick said. "I just wanted to be my healthy Jen Frederick again so I can get back to a normal life." A difficult treatment Frederick underwent gamma knife radiotherapy on January 7. The treatment uses precise gamma rays to target cancer tumors. Frederick said that it went well, but when she started receiving the biweekly immunotherapy medications on January 17, she began feeling "bad side effects," including "flu-like symptoms, rash, nausea," and high fevers. As she continued the treatment, the side effects expanded to include vomiting, chills and problems with her stomach and eyes. She was using the bathroom "25 plus times a day," Frederick said. She was hospitalized and spent a month in and out of the hospital. There was significant inflammation in her colon. She weighed only 95 pounds. "They would release me. I would go home. I'd be home 24 hours, and have to go back because I would just start vomiting again. I couldn't hold any food down," Frederick said. She had to take two months off from the immunotherapy to take steroids, antibiotics and other medications to treat the side effects. After recovering, she resumed treatment. When Frederick underwent her first PET scan since starting treatment, it showed "major, major improvement," she said. That made the months of pain, discomfort and illness worth it. A second scan several weeks later showed things were continuing to move "in the right direction," Frederick said. The immunotherapy was reduced to every three weeks, then every four weeks as she continued to improve. "My doctor said that I'm a Stage IV miracle," Frederick said. "Cancer does not have me" After 18 months of treatment, Frederick has not seen any progression of her cancer and continues to improve, her care team said. Kennedy believes that she has "a really excellent chance of having really long-term survival." Clinical trial patients who received the same treatment Frederick did are still doing well 10 years after the study, according to a recent update, Kennedy said. She believes Frederick will have a similar journey. "I only use the 10-year number because that's just as old as the drugs are. I think those patients will have responses that last beyond that, potentially indefinitely," Kennedy said. Frederick will continue her treatment until December 2025, Kennedy said. Then, she will start undergoing regular screening scans to make sure her cancer is not returning. Frederick said that once she is done with active treatment, she wants to share her story and make sure people know the importance of early screening. She has begun mentoring other cancer patients through the Cleveland Clinic's 4th Angel program. "I want people to know it gets harder before it's easier," Frederick said. "My saying has always been 'I may have cancer, but cancer does not have me.' And I want people to feel that way, because it isn't a death sentence." Wall Street Journal reports Trump sent "bawdy" birthday letter to Epstein, Trump threatens to sue Medical expert on Trump's chronic venous insufficiency diagnosis Americans on whether the U.S. should return to the moon, travel to Mars Solve the daily Crossword
CBS News
19-07-2025
- Health
- CBS News
Woman thought she had pulled a muscle working out. It was a rare cancer that had spread to her brain.
Jennifer Frederick was in the best shape of her life in 2023, so when she felt a small lump in her groin area after a week of workouts. She thought it was just a pulled muscle, but a month later, the lump was still there. Four months later, the lump was growing. Frederick went to a dermatologist and testing found more lumps in her leg. She scheduled a biopsy. On December 14, surgeons cut into her leg and removed the largest lumps. A week later, she had a diagnosis: Metastatic malignant melanoma. The disease is usually heralded by a mole on the skin, but Frederick never had one. More tests showed the cancer wasn't just in her leg. One scan found four lesions on her lungs. Another found five lesions on her brain. The results were shocking, Frederick said. "I never had a migraine, headache, blurry vision, never had problems breathing, never had a cough," Frederick, 50, said. "I never felt off at all." Melanoma is the deadliest form of skin cancer. Metastatic melanoma is any time of cancerous melanoma that has spread from one location to another, said Dr. Michael Postow, a medical oncologist at Memorial Sloan Kettering, who was not involved in Frederick's treatment. Metastatic malignant melanoma refers to late-stage metastatic melanoma. "Melanoma is a kind of cancer that can spread pretty widely throughout the body," Postow said. "It's one of the cancers that frequently involves the brain, so spread from melanoma to the brain ... can be quite a common occurrence. The lung is also a common site of metastatic melanoma." Typically, melanoma is recognized by a brown or black mole on the skin. Postow said it's unusual but not unheard of for a patient to have no mole or a "microscopic" one. He said that in addition to keeping an eye out for a new mole or an existing mole that changes color, size or texture, people should watch for lumps under the skin like the one Frederick had. Any concerns should be brought to a dermatologist, Postow said. The five-year survival rate for patients with advanced metastatic melanoma is about 35%, according to the American Cancer Society. Postow said clinical trials show that for patients who receive certain immunotherapy treatments, that number rises to 50%. Just a decade ago, the five-year survival rate was closer to 10%, he said. Immunotherapy was what Frederick's doctor, Cleveland Clinic medical oncologist Dr. Lucy Boyce Kennedy, recommended. The two talked over the options and decided to go with an intensive treatment that would combine gamma knife radiation and two immunotherapy drugs. Kennedy described the treatment protocol as "fairly high risk" and warned it could lead to the immune system attacking other organs. Frederick was undeterred. "She explained what this was going to look like. And I looked at her and I said, 'I don't care what it is. If it's the most aggressive treatment, I'm willing to do whatever it is,'" Frederick said. "I just wanted to be my healthy Jen Frederick again so I can get back to a normal life." Frederick underwent gamma knife radiotherapy on January 7. The treatment uses precise gamma rays to target cancer tumors. Frederick said that it went well, but when she started receiving the biweekly immunotherapy medications on January 17, she began feeling "bad side effects," including "flu-like symptoms, rash, nausea," and high fevers. As she continued the treatment, the side effects expanded to include vomiting, chills and problems with her stomach and eyes. She was using the bathroom "25 plus times a day," Frederick said. She was hospitalized and spent a month in and out of the hospital. There was significant inflammation in her colon. She weighed only 95 pounds. "They would release me. I would go home. I'd be home 24 hours, and have to go back because I would just start vomiting again. I couldn't hold any food down," Frederick said. She had to take two months off from the immunotherapy to take steroids, antibiotics and other medications to treat the side effects. After recovering, she resumed treatment. When Frederick underwent her first PET scan since starting treatment, it showed "major, major improvement," she said. That made the months of pain, discomfort and illness worth it. A second scan several weeks later showed things were continuing to move "in the right direction," Frederick said. The immunotherapy was reduced to every three weeks, then every four weeks as she continued to improve. "My doctor said that I'm a Stage IV miracle," Frederick said. After 18 months of treatment, Frederick has not seen any progression of her cancer and continues to improve, her care team said. Kennedy believes that she has "a really excellent chance of having really long-term survival." Clinical trial patients who received the same treatment Frederick did are still doing well 10 years after the study, according to a recent update, Kennedy said. She believes Frederick will have a similar journey. "I only use the 10-year number because that's just as old as the drugs are. I think those patients will have responses that last beyond that, potentially indefinitely," Kennedy said. Frederick will continue her treatment until December 2025, Kennedy said. Then, she will start undergoing regular screening scans to make sure her cancer is not returning. Frederick said that once she is done with active treatment, she wants to share her story and make sure people know the importance of early screening. She has begun mentoring other cancer patients through the Cleveland Clinic's 4th Angel program. "I want people to know it gets harder before it's easier," Frederick said. "My saying has always been 'I may have cancer, but cancer does not have me.' And I want people to feel that way, because it isn't a death sentence."
Yahoo
09-07-2025
- Business
- Yahoo
Top U.S. Health Systems Commit More Than $100M to Tackle Healthcare Staffing and Student Debt Crises
Boston Children's Hospital, Memorial Sloan Kettering, MyEyeDr., Northwestern Medicine, Novant Health, OhioHealth, VCA Animal Hospitals, and more offer early job commitments and a combined $101.2M+ in student loan repayment for critical healthcare roles. BOSTON, July 9, 2025 /PRNewswire/ -- Top U.S. health systems are taking bold, employer-led action to combat two converging crises: student debt and clinical staffing shortages. Together with Clasp, the first retention-driven recruitment platform, hospitals are launching a new model for financing education—one that locks in talent early, rewards retention, and makes healthcare careers more accessible. A new generation of healthcare professionals is entering the workforce with staggering debt—often exceeding $100,000 for roles like physical therapists, occupational therapists, and physician assistants, and nearly $150,000 for newly graduated veterinarians. These burdens are only expected to grow as more roles shift to advanced degree requirements: physical therapists now need a doctorate to practice, nurse anesthetists will soon face the same, and states like New York are mandating additional credentials like the "BSN in 10" rule for nurses. Clasp's model flips the script on traditional student loan benefits. Clasp programs enable employers to commit early—often while students are still in school—and defer actual repayment until after retention milestones. That structure stretches every dollar further, with many employers on Clasp's platform offering up to $75,000+ in tax-advantaged loan repayment over three years. The result: deeper loyalty, lower turnover, and more sustainable pipelines for in-demand roles like nurse anesthesia, radiologic and surgical technology, respiratory therapy, physical therapy, and veterinary medicine. Systems leading the charge include Boston Children's Hospital (ranked the #1 pediatric hospital in the country), Memorial Sloan Kettering (the #2 cancer center), MyEyeDr. (a leading national eye care provider), Northwestern Medicine (Illinois' top-ranked hospital system), Novant Health (a top 40 U.S. health system), OhioHealth (central Ohio's largest health system), and VCA Animal Hospitals (leading national veterinary group). They join Clasp's growing network of early adopters building stronger futures—for students and the healthcare workforce alike. "At Novant Health, we're working to build a healthier future for all – from patients and communities to our own clinicians and team members. We believe the workforce of tomorrow depends on how we support students today," said Sebastien Girard, Senior Vice President and Chief People Officer, Novant Health. "As part of our recruitment efforts targeting new nurse anesthetists, we've partnered with Clasp to repay a significant portion of their student loans and hope to expand this benefit to other positions in the future. By relieving financial burden upfront, we're building loyalty from day one—and setting a new bar for what it means to invest in our future teams." To expand access and impact, Clasp has also secured up to $100 million in no-cosigner education loan funding—helping students from low- and middle-income backgrounds pursue high-impact healthcare careers without barriers. "This isn't just about offering a benefit—it's about rewiring how healthcare systems attract and retain talent," said Tess Michaels, CEO of Clasp. "These leaders aren't just responding to a crisis. They're shaping the future of work in healthcare—and setting a new standard that others will follow." This Spring, a healthcare system with >30,000 employees fully replaced their sign-on bonuses for one of their hardest-to-hire clinical roles and was able to hit 130% of their applicant goal in just 20 days offering student loan repayment. Across Clasp's partner network, early data shows a potential 440% return-on-investment, with employers saving up to $5 million in year one by utilizing as an alternative to sign-on bonuses, reducing contract labor spend, and cutting turnover—down to as little as 5% in some roles on Clasp's platform. Building A Stronger Future, TogetherMomentum is building. Health systems nationwide are turning to this new model as a smarter, more sustainable way to build high-performing clinical teams—and students are responding. "If we want healthcare to be stronger tomorrow, we need to invest in the people who power it today," Michaels added. "This model works because it starts earlier, goes deeper, and delivers real, lasting results." Students currently enrolled in eligible programs can learn more and apply at Healthcare employers ready to lead—not follow—can reach out to partnerships@ to join the movement today. About ClaspClasp is a first-of-its-kind platform connecting education and employment through retention-driven recruitment. Since 2018, Clasp (formerly Stride Funding) has helped over 10,000 students access outcomes-based financing, career pathways, and student loan repayment. By enabling healthcare systems to sponsor loan repayment tied to early job commitments, Clasp addresses two major challenges: student debt and the clinical talent shortage. Clasp also publishes the School Deserts Index, a national report featuring state-by-state rankings of gaps in clinical training programs, offering actionable insights for workforce planners. Backed by up to $100M in funding capacity—with no co-signer required—Clasp supports students at the moment they need it most. Learn more at Media ContactMorgan ViehmanSr. Director, Brand & Marketingmorgan@ View original content to download multimedia: SOURCE Clasp Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
07-07-2025
- Health
- Medscape
Are Breast Cancer Survivors Vulnerable to Dementia?
Despite concerns about cognitive decline after cancer treatment, most breast cancer survivors show no increased risk of developing Alzheimer's disease, and some may have a slightly lower risk than their cancer-free peers, according to a large retrospective study from Korea. However, any apparent protective effect faded with time, the investigators reported online in JAMA Network Open . Overall, this is 'reassuring news for cancer survivors,' Tim Ahles, PhD, a psychologist with Memorial Sloan Kettering Cancer Center, New York City, who wasn't involved in the study, told Medscape Medical News. 'I get this question from patients a lot,' Ahles said. And based on these findings, 'it doesn't look like a history of breast cancer and breast cancer treatment increases your risk for Alzheimer's disease.' Breast cancer survivors often report cancer-related cognitive impairment, such as difficulties with concentration and memory, both during and after cancer treatment. But evidence surrounding patients' risk for Alzheimer's disease is mixed. One large study based in Sweden, for instance, reported a 35% increased risk for Alzheimer's disease among patients diagnosed with breast cancer after the age of 65 years, but not among younger patients. A population-based study from Taiwan, however, found no increase in the risk for dementia overall compared with cancer-free individuals but did note a lower dementia risk in patients who had received tamoxifen. To help clarify the evidence, investigators assessed Alzheimer's disease risk in a large cohort of patients and explored the association by treatment type, age, and important risk factors. Using the Korean National Health Insurance Service database, the researchers matched 70,701 patients who underwent breast cancer surgery between 2010 and 2016 with 180,360 cancer-free control individuals. The mean age of breast cancer survivors was 53.1 years. Overall, 72% received radiotherapy. Cyclophosphamide (57%) and anthracycline (50%) were the most commonly used chemotherapies, and tamoxifen (47%) and aromatase inhibitors (30%) were the most commonly used endocrine therapies. The primary outcome of this study was the incidence of newly diagnosed Alzheimer's disease, which was defined on the basis of at least one prescription for medications to manage dementia associated with Alzheimer's disease (donepezil, rivastigmine, galantamine, or memantine). During a median follow-up of about 7 years, 1229 newly diagnosed Alzheimer's disease cases were detected in breast cancer survivors and 3430 cases in control individuals — incidence rates of 2.45 and 2.63 per 1000 person-years, respectively. This corresponded to an 8% lower risk for Alzheimer's disease in breast cancer survivors compared with cancer-free control individuals at 6 months (subdistribution hazard ratio [SHR], 0.92; 95% CI, 0.86-0.98). The association was especially notable in survivors older than 65 years (SHR, 0.92; 95% CI, 0.85-0.99). Looking at individual treatment modalities, only radiation therapy was associated with significantly lower risk for Alzheimer's disease among breast cancer survivors (adjusted HR [aHR], 0.77). Several risk factors were associated with a significantly higher risk for Alzheimer's disease: current smoker vs never or ex-smokers (aHR, 2.04), diabetes (aHR, 1.58), and chronic kidney disease (aHR, 3.11). Notably, alcohol use, physical activity level, and hypertension were not associated with Alzheimer's disease risk. However, any potential protective effect may be short-lived. The reduced risk for Alzheimer's disease was no longer significant at 1 year (SHR, 0.94; 95% CI, 0.87-1.01), 3 years (SHR, 0.97; 95% CI, 0.90-1.05), or 5 years (SHR, 0.98; 95% CI, 0.89-1.08). Even so, breast cancer survivors can still feel reassured by the findings. 'Concerns about chemobrain and the long-term adverse effects of breast cancer treatment on cognition are common, but our findings suggest that this treatment does not directly lead to Alzheimer's disease,' wrote the authors, led by Su-Min Jeong, MD, with Seoul National University College of Medicine, Seoul, South Korea. Ahles agreed. The general takeaway from this study is that there is 'no strong evidence that the cancer treatment is going to increase your risk for developing Alzheimer's,' Ahles said. When patients ask about the risk for Alzheimer's disease, 'I can say, 'Here's yet another new study that supports the idea that there's no increased risk.'' He cautioned, however, that the study doesn't address whether people with a genetic predisposition to Alzheimer's might develop it sooner due to cancer treatment. 'Does the cancer treatment increase your probability or nudge you along? The study doesn't answer that question,' Ahles said.
Yahoo
03-07-2025
- Entertainment
- Yahoo
Bill Moyers, Longtime PBS and CBS Journalist and Documentarian, Dies at 91
Bill Moyers, the onetime White House Press Secretary and newspaper publisher who spent four decades as a respected broadcast journalist and documentarian for PBS and CBS, died Thursday. He was 91. Moyers died at Memorial Sloan Kettering Cancer Center in New York after a long illness, his son William told the Associated Press. More from The Hollywood Reporter Lalo Schifrin, Acclaimed Composer of 'Mission: Impossible' and 'Mannix' Themes, Dies at 93 Lea Massari, Italian Cinema's Anti-Diva, Dies at 91 Thomas H. Brodek, Former Film Producer and ABC Executive, Dies at 86 Moyers hosted, wrote for and/or produced PBS programs like Bill Moyers' Journal, Moyers & Company, A World of Ideas, Frontline, Now With Bill Moyers, Creativity With Bill Moyers and A Walk Through the 20th Century in stretches from 1971 through 2010, winning two Peabody Awards, three Humanitas Prizes and four Primetime Emmys along the way. An eloquent speaker with a soft Texas twang, he was a skillful longform interviewer who confronted social and political issues with incisive, folksy exploration. He was not afraid to state his point of view and supported liberal causes and organizations, including Fairness and Accuracy in Reporting and Take Back America. 'In an age of television shouters, Mr. Moyers is an anomaly,' David Carr wrote for The New York Times in 2004. 'His delivery is measured and the rhetoric temperate. Yet he used the tools of the documentarian to wield a velvet sledgehammer, bludgeoning corporate polluters and government ne'er-do-wells with precision and grace. His tendentiousness in choice of targets has earned him the fealty of public television audiences and the enmity of conservative observers.' In 1976, Moyers exited PBS to become editor and chief correspondent for CBS Reports. He also did On the Road mini-documentaries as well as analysis and commentary for the CBS Evening News With Dan Rather starting in 1981, drawing a salary of $1 million a year. In a bitter split, Moyers exited CBS in 1986 — he said the line between entertainment and news at the network had 'steadily blurred' — and formed his own company, Public Affairs Television, to distribute his programs. Transcribed versions were published as books, including Joseph Campbell and the Power of Myth, which remained on the Times' best-seller list for more than a year. Moyers was hailed by some as 'the conscience of America,' a trusted public figure in the mold of Walter Cronkite. He was considered a possible Democratic Party presidential candidate but never took the bait. In 2006, he received a Lifetime Achievement Emmy from the National Academy of Television Arts & Sciences for 'devoting his lifetime to the exploration of the major issues and ideas of our time and our country, giving television viewers an informed perspective on political and societal concerns.' On Thursday night, his death was acknowledged by NATAS chairman Terry O'Reilly at the 46th annual Documentary Awards in New York. Moyers, he said, 'was a whole lot happier telling the truth [as a journalist] than he was trying to hide it [while working in politics].' The youngest of two sons, Billy Don Moyers was born on June 5, 1934, in Hugo, Oklahoma. His father, Henry, was a truck driver and his mother, Ruby, a housewife. Raised in Marshall, Texas, he began his journalism career as a cub reporter on the Marshall News Messenger and was the editor of the sports page while still a sophomore at Marshall High School. At North Texas State College, he spent the summer of 1954 interning for Lyndon B. Johnson in Washington, getting the job after writing an 'audacious' letter to the Texas senator. 'I said to him, 'I can tell you something about young people in Texas if you can tell me something about politics,'' he recalled in a 2001 chat for the Television Academy Foundation website The Interviews. Moyers graduated from the University of Texas with a degree in journalism in 1956. As a student in Austin, he also worked at KTBC-TV, a station owned by Johnson's wife, Lady Bird Johnson. He then studied in Scotland for a year before attending Southwestern Baptist Theological Seminary in Fort Worth, landing a Master of Divinity degree in 1960. (He officiated the wedding of George Lucas and Mellody Hobson at Skywalker Ranch in 2013.) Moyers rejoined Lyndon Johnson, soon to be John F. Kennedy's pick for vice president, as his 'Man Friday' during the 1960 presidential campaign. He helped create the Peace Corps during the JFK administration in March 1961, reporting to the president's brother-in-law, Sargent Shriver, as deputy director. When Johnson became president after Kennedy's assassination, Moyers stayed on as his adviser and special assistant. He was highly involved in Johnson's 1964 re-election campaign against Republican Barry Goldwater and approved the controversial 'Daisy' TV commercial in which a girl counts the petals she plucks from a flower before another countdown leads to a nuclear explosion on the screen. 'It never mentioned Goldwater, it wasn't a personal attack,' Moyers said in his TV Archive interview. 'It was an assertion of concern over whose hand was on the nuclear trigger. It was a subliminal ad, though I didn't even know the meaning of that term then. [Goldwater] never forgave me for what he understood was my role in it, right up until the end of his life.' After Johnson's landslide triumph, Moyers served as White House Press Secretary from 1965-67 — a media darling, he was on the covers of Time and Newsweek during his first year on the job — before resigning to become publisher of Newsday in 1967. The Long Island newspaper hired columnist Pete Hamill and won two Pulitzer Prizes during his three-year tenure, which ended when Newsday was sold to the Times Mirror Co. (Moyers had put together a higher offer to buy the paper but was rebuffed.) He then traveled around the country for Harper's magazine for four months in a 'swing of rediscovery,' from which he wrote 1971's Listening to America, which became a best-seller. From that, New York public TV station WNET hired him to host a weekly half-hour that would become Bill Moyers' Journal. The program included the first major interview with Jimmy Carter before he was known outside of Plains, Georgia, as well as an acclaimed 'Essay on Watergate' in 1973. Moyers had a 'five years and out' philosophy, considering that for people to 'renew' themselves, they should move on every five years. That philosophy originated when he persuaded Congress to make that period of time the maximum for volunteer employment in the Peace Corps. He held that policy for public broadcasting, too. 'It's very important for [it] to open itself constantly to new people, to renew it,' he said. 'And that's not going to happen unless us old-timers move on.' He also worked for NBC and MSNBC in the mid-1990s. Moyers married North Texas State classmate Judith Davidson in December 1954 — she went on to serve as president of Public Affairs Television — and they had three children, William, John and Alice. Best of The Hollywood Reporter 'The Studio': 30 Famous Faces Who Play (a Version of) Themselves in the Hollywood-Based Series 22 of the Most Shocking Character Deaths in Television History A 'Star Wars' Timeline: All the Movies and TV Shows in the Franchise
